The Psychedelic CEO Round Table | feat. MindMed, Cybin, Field Trip and the Psychedelic Investor

Will Ark Invest (ARKK) and Cathie Wood invest in MindMed ( MMED / MMEDF/ MMQ) or other Psychedelic Stocks? In this episode, Cathie Wood talks to Kevin O’Leary about the potential for psychedelic stocks and MindMed.

Kevin O’Leary is a BIG bull in MindMed, but what does Cathie Wood think? Will Ark invest in MindMed? Well, no. She is clear that Ark does not invest in binary outcomes, which MMED / MMEDF cleary is.

Having said this, the door may be left open for the future, as ARKK invests in Healthcare companies using artifical intellegence, exactly what MindMed’s Albert division is working on. Also, once clinical trial results come in, MindMed will no longer be a binary choice. SO anything is possible.

I hope this little impromptu episode added some life and joy to your live and that you guys found some value in this.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​​ ​#MindmedNews​​​ #PsychedelicStocks

When it comes to investing in psychedelic stocks such as MindMed (MNMD, MMED), Compass Pathways (CMPS), atai Life Sciences (ATAI), Cybin (CYBN) and more, even if we have a solid long term thesis, the short term is very volatile.

To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

PS: THIS IS NOT INVESTING ADVICE, JUST MY OPINION.

In this video, I will discuss what to look out for, both the positives and the negatives, in the coming months. What are the catalysts? What are the risks?
The main thing to understand, is that the market cares more about short term profit than it does long term indicators. Right now, we are seeing psychedelic medicine clinical trials showing fantastic results, but we should not expect the market to react until we are closer to commercialization.
There are also many macro risks to be aware of, and general all around volatility. But we need to remember, short term swings do not affect the long-term thesis.

Links:
Awakn Phase 2 Ketamine Therapy for Alcohol Use Disorder:
https://psychedelicspotlight.com/ketamine-trial-alcohol-use-disorder-promising-results-awakn-life-sciences/

MAPS Phase 3 MDMD for PTSD Trial
https://psychedelicspotlight.com/first-phase-3-trial-mdma-assisted-therapy-ptsd/

Compass Pathways Phase 2b Psilocybin for Depression Trial
https://psychedelicspotlight.com/compass-pathways-largest-psilocybin-therapy-trial-ever-depressive-symptoms-rapidly-reduce/

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#PsychedelicStocks #MindMed #Cybin

How long until Psychedelic Stocks Payoff?🍄🚀

To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.

And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.

In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”

Or, translated to Reddit-speak: when moon?

To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.

There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.

The first will happen relatively soon.

#PsychedelicStocks #MindMed #Cybin

Happy Holidays guys! I 🎄🙃 In this episode we’ll cover the many reasons why I’m more excited about MindMed’s 18-MC than its LSD treatments. As I mentioned in my previous video, the unfortunate fact is that the world is dealing with a second hidden epidemic: The Opioid Crisis. MindMed ( MMED/ MMEDF ) has a solution: 18-MC. Yes, MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. However, this psychedelic medicines company has its own proprietary compound (18-MC) to treat addiction which, if successful, cannot be copied by the upcoming competition. Keep watching to learn more about MindMed’s plan to end the opioid crisis with 18-MC. We may have a light at the end of the tunnel, and MindMed could potentially defeat the opioid epidemic threat, making MMED one of the best stocks for 2021.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF
#mindmedstock